Navigation Links
Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
Date:10/1/2010

PASADENA, Calif., Oct. 1 /PRNewswire/ -- Maven Biotechnologies today announced that the company has been awarded $1.96 million by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH, to support the commercialization of their LFIRETM imaging technology for label-free protein microarrays and cell-based assays. The highly competitive grant was awarded to Maven through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN).

(Logo: http://photos.prnewswire.com/prnh/20101001/LA75512LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101001/LA75512LOGO)

"Maven welcomes the support of the NIH to bring our platform to market," says Chief Technology Officer David Ralin. "LFIRETM's label-free, multiplexed capabilities and inherent simplicity will directly benefit our customers, delivering better results in less time and with lower costs." Target applications for the technology include - but are not limited to - immunoassays in the research and diagnostics markets, cell-based studies, high-throughput pharmaceuticals screening and the established label-free applications in biomolecular interaction analysis.

Chief Engineering Officer Jeffrey Chongsathien M.A. Cantab. adds, "We look forward to creating a robust, flexible and modular product portfolio of laboratory instrumentation and consumables, built on LFIRETM." The initial instrument will be a desktop microplate reader, with a set of 'alpha' evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.

Company Founder and CEO William Rassman M.D. noted that the grant will 'jump-start' the commercialization of the product and will be the forerunner of other funding events.

About Maven Biotechnologies

Maven Biotechnologies (www.mavenbiotech.com) is a privately-held biotechnology company located in Pasadena, CA. The company has developed LFIRE™ [pronounced: el - fire] - a flexible, cost-effective, high density imaging technology for the multiplexed, quantitative, label-free, real-time characterization of biomarker binding reactions. The platform addresses applications in biomedical research, drug discovery, immunodiagnostics, biodefense, biological manufacturing and point-of-care. Maven holds 14 granted US and international patents.


'/>"/>
SOURCE Maven Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
6. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
7. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... ... January 19, 2017 , ... November ... to leading biopharmaceutical and medical device manufacturers and regulators, is proud to announce ... Part 11-compliant email client designed to provide product vigilance departments with the flexibility ...
(Date:1/19/2017)... Yorba Linda, Ca (PRWEB) , ... January 18, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... Corporate American News. The awards program is based entirely on merit and decided ...
Breaking Biology Technology:
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):